European DNBSEQ Users Demonstrate Q40 Quality with StandardMPS 2.0 Chemistry

MGI Unveils DNBelab C-TaiM 4 Single-Cell Droplet Generator at ESHG 2024

BERLIN, Germany, 3 June 2024 – MGI (MGI Tech Co., Ltd. and its subsidiaries), a leading innovator in life science technologies, showcased groundbreaking advancements at the European Society of Human Genetics (ESHG) conference in Berlin. This year's event highlighted early access data demonstrating Q40 quality using the updated StandardMPS 2.0 sequencing chemistry and the introduction of MGI’s new DNBelab C-TaiM 4 Single-Cell Droplet Generator.

European Researchers Highlight MGI’s DNBSEQ Technology

Researchers and clinicians from across Europe presented compelling insights on the adoption of MGI’s core DNBSEQ™ technology in diverse applications, including screening, diagnostics, and population health initiatives. Notable presentations included:

• Dr. Davide Cacchiarelli from the Telethon Institute of Genetics and Medicine in Italy emphasized how DNBSEQ enables affordable screening services for the Italian population.

• Dr. Paula Sancho Salmerón from Sistemas Genómicos in Spain showcased a diagnostic workflow for monogenic hereditary diseases.

• Daniel Langhoff, Senior Director for Population & Consumer Genomics at Eurofins in Germany, discussed a multi-omics approach to population health using MGI’s sequencing technology.

Quality Advancements with StandardMPS 2.0 Sequencing Chemistry

Dr. Marie-Laure Yaspo from Germany’s ALACRIS Theranostics provided an in-depth look at the significant quality improvements achieved with the new StandardMPS 2.0 (SM 2.0) sequencing chemistry. First announced at AGBT 2024, SM 2.0’s updated reagents and software deliver base quality scores reaching or exceeding Q40 in 85% of sequences on the DNBSEQ platform. This enhancement underscores MGI’s commitment to innovation, quality, and cost-effectiveness without requiring changes to the instrument platform.

Launch of DNBelab C-TaiM 4 Single-Cell Droplet Generator

At the ESHG conference, MGI also launched its latest innovation, the DNBelab C-TaiM 4 Single-Cell Droplet Generator. This device is designed to generate high-throughput single-cell RNA libraries compatible with DNBSEQ instruments, including the DNBSEQ-G400, DNBSEQ-T7, and DNBSEQ-T20×2, expanding the capabilities of single-cell research.

MGI’s Commitment to Innovation and Quality

“I’m delighted that MGI is able to showcase new product and technological developments year on year during the premier genomics event in the region,” said Dr. Yong Hou, General Manager of MGI Europe and Africa. “We are thrilled to share with visitors our portfolio of sequencers and the new single-cell device, as MGI continues to open new possibilities for DNBSEQ users, particularly in the European and African markets."

Empowering the Future of Genomics

MGI’s DNBSEQ technology, renowned for its cost-effectiveness, accuracy, and technical capabilities, continues to provide reliable and efficient sequencing solutions for both research and clinical applications. By driving innovation in sequencing and relevant products, MGI empowers the life science community to advance into the future of genomics.

For More Information

To learn more about the DNBelab C-TaiM 4 Single-Cell Droplet Generator, visit here.

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users, and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit the mgi-tech.eu or connect on Twitter, LinkedIn, or YouTube.